Tarsus Pharmaceuticals (TARS)

• Market cap: $2.07B
• 1 day: -0.68%
• 5 days: 0.80%
• 1 month: 11.84%
• 3 months: 63.61%
• 6 months: 104.39%
• Year to date: 168.06%
• 1 year: 168.06%
• 5 years: 162.59%
• 10 years: 162.59%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Employees: 244

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

12,880% more call options, than puts

Call options by funds: $17.5M | Put options by funds: $135K

100% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 8 (+4) [Q3]

54% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 26

24% more capital invested

Capital invested by funds: $1.15B [Q2] → $1.43B (+$275M) [Q3]

20% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 45

9% more funds holding

Funds holding: 148 [Q2] → 162 (+14) [Q3]

1.88% more ownership

Funds ownership: 112.31% [Q2] → 114.19% (+1.88%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $41 24% downside
• Avg. target: $53 2% downside
• High target: $65 20% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Goldman Sachs Andrea Tan 36% 1-year accuracy 4 / 11 met price target	24% downside $41	Neutral Maintained	15 Nov 2024
Oppenheimer Francois Brisebois 43% 1-year accuracy 15 / 35 met price target	20% upside $65	Outperform Maintained	14 Nov 2024